B. TÜYSÜZ Et Al. , "Investigation of 11p15.5 Methylation Defects Associated with Beckwith-Wiedemann Spectrum and Embryonic Tumor Risk in Lateralized Overgrowth Patients," CANCERS , vol.15, no.6, 2023
TÜYSÜZ, B. Et Al. 2023. Investigation of 11p15.5 Methylation Defects Associated with Beckwith-Wiedemann Spectrum and Embryonic Tumor Risk in Lateralized Overgrowth Patients. CANCERS , vol.15, no.6 .
TÜYSÜZ, B., BOZLAK, S., ULUDAĞ ALKAYA, D., OCAK, S., Kasap, B., ÇİFÇİ SUNAMAK, E., ... ŞEKER, A.(2023). Investigation of 11p15.5 Methylation Defects Associated with Beckwith-Wiedemann Spectrum and Embryonic Tumor Risk in Lateralized Overgrowth Patients. CANCERS , vol.15, no.6.
TÜYSÜZ, BEYHAN Et Al. "Investigation of 11p15.5 Methylation Defects Associated with Beckwith-Wiedemann Spectrum and Embryonic Tumor Risk in Lateralized Overgrowth Patients," CANCERS , vol.15, no.6, 2023
TÜYSÜZ, BEYHAN Et Al. "Investigation of 11p15.5 Methylation Defects Associated with Beckwith-Wiedemann Spectrum and Embryonic Tumor Risk in Lateralized Overgrowth Patients." CANCERS , vol.15, no.6, 2023
TÜYSÜZ, B. Et Al. (2023) . "Investigation of 11p15.5 Methylation Defects Associated with Beckwith-Wiedemann Spectrum and Embryonic Tumor Risk in Lateralized Overgrowth Patients." CANCERS , vol.15, no.6.
@article{article, author={BEYHAN TÜYSÜZ Et Al. }, title={Investigation of 11p15.5 Methylation Defects Associated with Beckwith-Wiedemann Spectrum and Embryonic Tumor Risk in Lateralized Overgrowth Patients}, journal={CANCERS}, year=2023}